Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement - (FIGHT-203) [Phase 2]

View source ↗

Summary

Phase 2 study FIGHT-203 evaluating pemigatinib in myeloid/lymphoid neoplasms with FGFR1 rearrangement has completed and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myeloid Lymphoid Neoplasms with Fgfr1 Rearrangement

Drugs mentioned

• Pemazyre (pemigatinib)

Snippet

Sponsor: Incyte Corporation | Conditions: MPN (Myeloproliferative Neoplasms) | Phase 2 | Status: COMPLETED | Results posted: 2025-11-18